Brianna Hoffner Discusses Complex Immune-Related Adverse Events

Video

Brianna Hoffner, MSN, NP, RN, discusses complex immune-related adverse events and how nurses can go about treating patients.

At the 2016 SITC Annual Meeting, Brianna Hoffner, MSN, NP, RN, from the University of Colorado Cancer Center discusses complex immune-related adverse events and the considerations that should go in to treating them.

In the example Hoffner uses, the cause of the patient’s symptoms must be parsed out, to discover which are the result of the immunotherapy agents. In this case, further diagnostic imaging provided the answer—that the patient was experiencing both pneumonitis and colitis concurrently.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
2 experts are featured in this series.
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Image of a woman with a blue background
5 experts in this video
5 experts in this video
Image of a man in scrubs with short hair and glasses
Photo of a woman with brown hair and bangs, surrounded by a blue border
Related Content
doctor in white coat holding hand out with the word "immunotherapy" floating above

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Russ Conroy
November 12th 2024
Article

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

Lindsay Fischer
February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

kidney cancer

Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

Gina Mauro
June 17th 2023
Article

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

Brielle Benyon
August 15th 2020
Podcast

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

FDA

Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

Kristi Rosa
April 24th 2023
Article

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.